Arcutis Biotherapeutics

Valuation Analysis

About the Company

Arcutis Biotherapeutics en bref

Arcutis Biotherapeutics (ARQT) is currently trading at 22,85 € with a market capitalization of 2,9 Md €. The 52-week range spans from 11,39 € to 27,70 €; the current price is 17.5% below the yearly high. Year-over-year revenue growth stands at +60.1%.

💰 Dividende

Arcutis Biotherapeutics currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

8 analystes évaluent Arcutis Biotherapeutics (ARQT) au consensus : Achat Fort. L'objectif de cours moyen est de 30,18 €, soit un potentiel de +32.11% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 28,77 € à 31,38 €.

Arcutis Biotherapeutics : la thèse d'investissement en détail

Arcutis Biotherapeutics (ARQT) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 60.1% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 90.94%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 32.11% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 13.84% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

The EV/EBITDA multiple of 567.74x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The analyst consensus price target implies 32.11% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to above-average price swings, elevated short interest (13.84%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Arcutis Biotherapeutics?

Compare top-rated brokers — low fees, trusted providers, fully regulated.